摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(4-bromothiophen-2-ylmethylene)-2-thioxodihydropyrimidine-4,6-dione

中文名称
——
中文别名
——
英文名称
5-(4-bromothiophen-2-ylmethylene)-2-thioxodihydropyrimidine-4,6-dione
英文别名
5-[(4-Bromothiophen-2-yl)methylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione
5-(4-bromothiophen-2-ylmethylene)-2-thioxodihydropyrimidine-4,6-dione化学式
CAS
——
化学式
C9H5BrN2O2S2
mdl
——
分子量
317.187
InChiKey
IALQNYWAABEWAS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    119
  • 氢给体数:
    2
  • 氢受体数:
    4

文献信息

  • Barbituric acid analogs as therapeutic agents
    申请人:——
    公开号:US20030229108A1
    公开(公告)日:2003-12-11
    This invention pertains to active barbituric acid analogs which inhibit HIF-1 activity (e.g., the interaction between HIF-1&agr; and p300) and thereby inhibit angiogenesis, tumorigensis, and proliferative conditions, such as cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HIF-1 activity, and to inhibit angiogensis, tumorigensis, and proliferative conditions, such as cancer.
    这项发明涉及活性巴比妥酸类似物,其抑制HIF-1活性(例如,HIF-1α与p300之间的相互作用),从而抑制血管生成、肿瘤发生和增生性疾病,如癌症。本发明还涉及包括这些化合物的药物组合物,以及在体外和体内使用这些化合物和组合物来抑制HIF-1活性,以及抑制血管生成、肿瘤发生和增生性疾病,如癌症。
  • BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS
    申请人:Novuspharma S.p.A.
    公开号:EP1305026A2
    公开(公告)日:2003-05-02
  • [EN] BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS<br/>[FR] ANALOGUES DE L'ACIDE BARBITURIQUE UTILISES COMME AGENTS THERAPEUTIQUES
    申请人:PROLIFIX LTD
    公开号:WO2001093841A2
    公开(公告)日:2001-12-13
    This invention pertains to active barbituric acid analogs which inhibit HIF-1 activity (e.g., the interaction between HIF-1α and p300) and thereby inhibit angiogenesis, tumorigenesis, and proliferative conditions, such as cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HIF-1 activity, and to inhibit angiogenesis, tumorigenesis, and proliferative conditions, such as cancer.
查看更多